These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. Yates CM; Brown PJ; Stewart EL; Patten C; Austin RJ; Holt JA; Maglich JM; Angell DC; Sasse RZ; Taylor SJ; Uings IJ; Trump RP J Med Chem; 2010 Jun; 53(11):4531-44. PubMed ID: 20469868 [TBL] [Abstract][Full Text] [Related]
4. Synthesis of novel steroidal agonists, partial agonists, and antagonists for the glucocorticoid receptor. Jin Z; Lin H; Srinivasan S; Nwachukwu JC; Bruno N; Griffin PR; Nettles KW; Kamenecka TM Bioorg Med Chem Lett; 2017 Jan; 27(2):347-353. PubMed ID: 27919657 [TBL] [Abstract][Full Text] [Related]
5. Discovery of indazole ethers as novel, potent, non-steroidal glucocorticoid receptor modulators. Hemmerling M; Edman K; Lepistö M; Eriksson A; Ivanova S; Dahmén J; Rehwinkel H; Berger M; Hendrickx R; Dearman M; Jensen TJ; Wissler L; Hansson T Bioorg Med Chem Lett; 2016 Dec; 26(23):5741-5748. PubMed ID: 27810243 [TBL] [Abstract][Full Text] [Related]
6. The selective glucocorticoid receptor agonist mapracorat displays a favourable safety-efficacy ratio for the topical treatment of inflammatory skin diseases in dogs. Bäumer W; Rossbach K; Schmidt BH Vet Dermatol; 2017 Feb; 28(1):46-e11. PubMed ID: 27425245 [TBL] [Abstract][Full Text] [Related]
7. SEGRAs: a novel class of anti-inflammatory compounds. Schäcke H; Hennekes H; Schottelius A; Jaroch S; Lehmann M; Schmees N; Rehwinkel H; Asadullah K Ernst Schering Res Found Workshop; 2002; (40):357-71. PubMed ID: 12355726 [TBL] [Abstract][Full Text] [Related]
8. Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate. Berger M; May E; Rehwinkel H; Schäcke H; Neuhaus R; Rottmann A; Zollner TM; Jaroch S Bioorg Med Chem Lett; 2020 Aug; 30(16):127298. PubMed ID: 32631518 [TBL] [Abstract][Full Text] [Related]
9. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Schäcke H; Schottelius A; Döcke WD; Strehlke P; Jaroch S; Schmees N; Rehwinkel H; Hennekes H; Asadullah K Proc Natl Acad Sci U S A; 2004 Jan; 101(1):227-32. PubMed ID: 14694204 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent series of non-steroidal non α-trifluoromethyl carbinol glucocorticoid receptor agonists with reduced lipophilicity. Diallo H; Angell DC; Barnett HA; Biggadike K; Coe DM; Cooper TW; Craven A; Gray JR; House D; Jack TI; Keeling SP; Macdonald SJ; McLay IM; Oliver S; Taylor SJ; Uings IJ; Wellaway N Bioorg Med Chem Lett; 2011 Feb; 21(4):1126-33. PubMed ID: 21257309 [TBL] [Abstract][Full Text] [Related]